Limited (LON:HCM – Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 274.45 ($3.38) and traded as low as GBX 232.04 ...

Hutchmed, a biopharmaceutical company controlled by Hong Kong’s wealthiest person Li Ka-shing, is divesting a 45% stake in a cardiovascular joint venture for about ...

Limited (HK:0013), backed by Hong Kong billionaire Li Ka-Shing, gained nearly 4% today after it agreed to sell 45% of its stake in its joint venture, Shanghai Hutchison Pharmaceuticals Limited (SHPL).

Biopharmaceutical firm Hutchmed China Ltd., backed by billionaire Li Ka-shing, has agreed to sell stakes in a health unit for about $608 million as the group seeks to generate capital and focus on its ...

HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New ...

HUTCHMED (China) Limited (NASDAQ:HCM – Get Free Report)’s stock price gapped up before the market opened on Friday . The stock had previously closed at $13.32, but opened at $13.99.

Hutchmed (HCM) announces that it has entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals for ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 01, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) announces that it has entered into two ...

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS ® (savolitinib) has been granted approval by the China National Medical ...

Focused R&D investment includes HUTCHMED's proprietary antibody-targeted therapy conjugate platform, with first candidates expected to enter clinical trials in the second half of 2025 - HONG KONG and ...